李凯军博士是摩珈生物的董事会主席和醴泽资本的管理合伙人。摩珈生物是一个致力于利用可再生碳源和绿色工艺生产食品成分和化学材料的全球化生物制造公司，在中国、美国和新加坡拥有实验室和产业化基地。醴泽资本是一家全球性生物科技投资机构。李博士在美国和中国拥有25年的创业和投资经验。他参与创立和管理了多家成功的生物科技公司，其中包括昆翎医药、晨泰医药和摩珈生物科技。李博士拥有印第安纳大学生物学博士学位，并在斯坦福大学医学院进行了博士后研究。此外，李博士担任多家成功的生物科技公司的投资者和董事会成员，其中包括凯赛生物、微芯生物、晨泰医药、Neurelis、Qpex、Jumpcode、Onchilles和Wugen等。

　　Dr. Kevin Li is the Chairman of Mojia Biotech and a Managing Partner at LYZZ Capital. Mojia Biotech is a global bio-manufacturing company that produces food ingredients and bio-based materials using renewable carbon sources and green processes, with research and manufacturing sites in China, the US and Singapore. LYZZ Capital is a leading global biotech venture capital fund. Dr. Li has over 25 years of experience as an entrepreneur and active biotech investor in the US and Asia. Kevin co-founded and managed several successful biotech companies, including ClinChoice, Alpha Biopharma, and Mojia Biotech. Dr. Li received his Ph.D. in biology from Indiana University and was a postdoctoral fellow at Stanford University School of Medicine. Dr. Li has been an investor and board member of many successful biotech companies, including Cathay Industrial Biotech, Chipscreen, Alpha Biopharma, Neurelis, Qpex, Jumpcode, Onchilles, and Wugen, among others.■